Corrigendum to 'Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care' Primary Care Diabetes 13 (6) (2019) 485-494

摘要

The authors would like to inform the readers that errors were made in the original article. The authors wish to revise the following contents: - Page 487, section 2.2, 3rd paragraph, second bullet: or radiopharmaceuticals (Iohexol) this should be or non-ionic iodinated contrast medium (Iohexol). - Page 490, Figure 3: for a better understanding, replace Figure 3 in colour instead of black and white.- Page 490, Figure 3: add in the footnotes Reproduced with permission of International Society of Nephrology (copyright 2018) and *The magnitude of a slope, connected to a hard outcome, requires further research (i.e., an eGFR decline of 8 ml/min per year over 2 years of follow-up, based on 7 creatinine/cystatine C measurements). Solid-line arrows indicate a "hard" impact on MARE; dotted-line arrows indicate a markedly lower impact or markers should be used as additional secondary endpoints only.